Armata Pharmaceuticals, Inc.

Armata Pharmaceuticals, Inc. is a clinical-stage biotechnology company dedicated to developing pathogen-specific bacteriophage therapeutics. The company's core mission is to combat antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Headquartered in Los Angeles, California, Armata operates a 56,000 square foot facility equipped for phage product development, spanning from research to clinical application, and includes in-house cGMP manufacturing capabilities.

Armata is advancing a pipeline of natural and synthetic phage candidates designed to precisely target bacterial pathogens. Key product candidates include AP-SA02, which is being developed for the treatment of Staphylococcus aureus bacteremia, and AP-PA02/AP-PA03, aimed at addressing Pseudomonas aeruginosa infections, particularly chronic pulmonary infections in patients with cystic fibrosis or bronchiectasis, and acute ventilator-associated pneumonia.

Recent notable developments include the appointment of Dr. Deborah L. Birx as CEO in July 2023. In May 2026, Armata Pharmaceuticals announced its first-quarter results and secured FDA Fast Track Designation for AP-SA02. The company also commissioned a state-of-the-art cGMP phage manufacturing facility in Los Angeles in November 2025, enhancing its capabilities for clinical trial material production and potential commercialization. Armata has received significant financing through secured credit agreements with Innoviva Strategic Opportunities LLC, a wholly-owned subsidiary of Innoviva, Inc., which is also Armata's largest shareholder.